RMB, we are actually at about $160M right now, not $250M. But at some point, Europe should start to ramp the way the U.S. did post-R-It, pre-Du. Remember, they achieved $600M+ in 2020. Plus, new formulation and Authorized Generic will likely help them re-capture some (or all) of the U.S. market.
But Europe will take a bit longer to ramp because the marketing model is so different than the U.S. And maybe within 5 years we get Germany on board as well.
As I said, if we cannot achieve $500M in peak worldwide revenues, then Vascepa is basically doomed as a product.
It's definitely an uphill battle to get this product out to market. It's being treated like the kid-brother of CVD treatment right now. That's why I think Sarissa has bigger plans with the new formulation. Sort of a "re-introduction" of the product. Only my opinion, though. I don't have too much to back that up yet.
Market Data 
Markets 
AI
